Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events
Stroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antip...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/8/1721 |
| _version_ | 1797537471992430592 |
|---|---|
| author | Leonardo De Luca Elisa Bellettini Dario Di Maio Enrico Natale Rita Lucia Putini Sabrina Anticoli Furio Colivicchi Paolo Calabrò Francesco Musumeci Domenico Gabrielli |
| author_facet | Leonardo De Luca Elisa Bellettini Dario Di Maio Enrico Natale Rita Lucia Putini Sabrina Anticoli Furio Colivicchi Paolo Calabrò Francesco Musumeci Domenico Gabrielli |
| author_sort | Leonardo De Luca |
| collection | DOAJ |
| description | Stroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antiplatelet therapy may play a key role in the management of non-cardioembolic cerebrovascular events. This review will focus on the current evidence of antiplatelet therapies most commonly discussed in practice guidelines and used in clinical practice for the treatment of stroke/TIA complications. The antiplatelet therapies most commonly used and discussed are as follows: aspirin, clopidogrel, and ticagrelor. |
| first_indexed | 2024-03-10T12:16:38Z |
| format | Article |
| id | doaj.art-996fad7ca8954391ab741d3b7c492e5b |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T12:16:38Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-996fad7ca8954391ab741d3b7c492e5b2023-11-21T15:49:52ZengMDPI AGJournal of Clinical Medicine2077-03832021-04-01108172110.3390/jcm10081721Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular EventsLeonardo De Luca0Elisa Bellettini1Dario Di Maio2Enrico Natale3Rita Lucia Putini4Sabrina Anticoli5Furio Colivicchi6Paolo Calabrò7Francesco Musumeci8Domenico Gabrielli9Division of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyDivision of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyDivision of Cardiology, Department of Translational Medicine, University of Campania Luigi Vanvitelli, 81100 Caserta, ItalyDivision of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyDivision of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyStroke Unit, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyDivision of Cardiology, S. Filippo Neri Hospital, 00135 Rome, ItalyDivision of Cardiology, Department of Translational Medicine, University of Campania Luigi Vanvitelli, 81100 Caserta, ItalyCardiac Surgery Unit and Heart Transplantation Center, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyDivision of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, ItalyStroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antiplatelet therapy may play a key role in the management of non-cardioembolic cerebrovascular events. This review will focus on the current evidence of antiplatelet therapies most commonly discussed in practice guidelines and used in clinical practice for the treatment of stroke/TIA complications. The antiplatelet therapies most commonly used and discussed are as follows: aspirin, clopidogrel, and ticagrelor.https://www.mdpi.com/2077-0383/10/8/1721antiplatelet therapyaspirinclopidogrelticagrelorstrokeTIA |
| spellingShingle | Leonardo De Luca Elisa Bellettini Dario Di Maio Enrico Natale Rita Lucia Putini Sabrina Anticoli Furio Colivicchi Paolo Calabrò Francesco Musumeci Domenico Gabrielli Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events Journal of Clinical Medicine antiplatelet therapy aspirin clopidogrel ticagrelor stroke TIA |
| title | Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events |
| title_full | Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events |
| title_fullStr | Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events |
| title_full_unstemmed | Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events |
| title_short | Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events |
| title_sort | oral antiplatelet therapy for secondary prevention of non cardioembolic ischemic cerebrovascular events |
| topic | antiplatelet therapy aspirin clopidogrel ticagrelor stroke TIA |
| url | https://www.mdpi.com/2077-0383/10/8/1721 |
| work_keys_str_mv | AT leonardodeluca oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT elisabellettini oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT dariodimaio oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT enriconatale oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT ritaluciaputini oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT sabrinaanticoli oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT furiocolivicchi oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT paolocalabro oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT francescomusumeci oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents AT domenicogabrielli oralantiplatelettherapyforsecondarypreventionofnoncardioembolicischemiccerebrovascularevents |